1. Home
  2. GROY vs URGN Comparison

GROY vs URGN Comparison

Compare GROY & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GROY

Gold Royalty Corp.

HOLD

Current Price

$3.30

Market Cap

1.0B

Sector

N/A

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$17.13

Market Cap

922.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GROY
URGN
Founded
2020
2004
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
922.1M
IPO Year
2020
2016

Fundamental Metrics

Financial Performance
Metric
GROY
URGN
Price
$3.30
$17.13
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
7
Target Price
$5.90
$29.29
AVG Volume (30 Days)
2.8M
781.6K
Earning Date
03-18-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$147.12
$127.17
Revenue Next Year
$51.16
$73.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.23
$3.42
52 Week High
$5.45
$30.00

Technical Indicators

Market Signals
Indicator
GROY
URGN
Relative Strength Index (RSI) 34.11 35.82
Support Level $3.03 $17.07
Resistance Level $4.01 $20.44
Average True Range (ATR) 0.19 0.89
MACD -0.06 -0.08
Stochastic Oscillator 19.55 12.96

Price Performance

Historical Comparison
GROY
URGN

About GROY Gold Royalty Corp.

Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: